Reactions Weekly | 2021
Multiple drugs
Abstract
Acute pancreatitis: 14 case reports In a retrospective, cohort study involving 47 patients who had been hospitalised due to drug-induced acute pancreatitis (DIAP) between January 2008 and January 2018, 14 patients (4 women and 10 men) aged 29–90 years* were described, who developed acute pancreatitis (AP) following treatment with asparaginase, dexketoprofen, doxycycline, eslicarbazepine acetate, everolimus, ibuprofen, indapamide, interferon-α-2a, losartan, mercaptopurine, metronidazole, pitavastatin, repaglinide, tigecycline, torasemide or vildagliptin. The patients presented to hospital and were diagnosed to have AP. Upon evaluation, the culprit drugs were determined to be immunosuppressant therapy with everolimus (n=1), antibiotic therapy with doxycycline (n=1), metronidazole (n=1) and tigecycline (n=1), NSAID therapy with dexketoprofen (n=1) and ibuprofen (n=1), diuretic therapy with torasemide (n=1) and indapamide (n=1), oral anti-diabetic therapy with vidagliptin and repaglinide (n=1) and treatments with asparginase (n=1), eslicarbazepine acetate [eslicarbamazepine; n=1], losartan (n=1), pitavastatin (n=1) and interferon-α-2a (n=1) according to Badalov’s class III (n=6), Ia (n=2), Ib (n=2), IV (n=1) and II (n=3) [not all routes and indications stated; dosages and times to reactions onsets not stated]. Therefore, the patients were hospitalised due to DIAP. One patient, who had developed initial episode of AP secondary to asparginase, developed another episode of AP secondary to mercaptopurine, and another patient, who had developed doxycylineinduced DIAP, presented gallstone pancreatitis [aetiology unknown] during the follow-up period [outcomes of ADRs not stated].